Please login to the form below

Not currently logged in
Email:
Password:

opioid abuse

This page shows the latest opioid abuse news and features for those working in and with pharma, biotech and healthcare.

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

AcelRX’ s potent opioid tablets set to win FDA backing for pain relief. ... Opioid abuse has reached epidemic proportions in the US, and the FDA has played its part in refusing approval to treatments that could be abused, while promoting treatments

Latest news

  • Heron boosted by new data for ‘breakthrough’ pain drug Heron boosted by new data for ‘breakthrough’ pain drug

    opioid analgesics compared to both placebo and local anaesthesia monotherapy with bupivacaine in the first 48 hours after surgery. ... The reduction in opioid use is another important facet of the new therapy, given the US’s current epidemic of opioid

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    naloxone), another treatment for opioid dependence, and which raised the threat of low-cost copies reaching the market earlier than expected. ... Opioid abuse has become such an acute problem in the US that President Trump signed an executive order last

  • FDA approves first substance use mobile medical application FDA approves first substance use mobile medical application

    Reset works by teaching users skills to increase their abstinence from substance abuse and keep them in outpatient therapy programmes. ... The trial did not demonstrate the effectiveness of using Reset for opioid abuse and the application is not licensed

  • Endo faces industry-first FDA call to pull its opioid painkiller Endo faces industry-first FDA call to pull its opioid painkiller

    abuse.”. Opioid overdoses killed 33, 000 Americans in 2015 - with half of those involving a prescription opioid. ... Previously Purdue Pharma’s opioid painkiller Oxycontin was removed from the market when an abuse-resistant form became available, but

  • A rock and a hard place A rock and a hard place

    Without the tamper-resistant packaging, critics argued that the FDA was ignoring the high potential for opioid abuse and the ramifications that came along with that. ... 51. Achievement of narrow targets and the potential for abuse are very different

More from news
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics